Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizoaffective Disorder
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
- Trial name
- NCT00325689
- Testing
- Quetiapine or Risperidone + Aripiprazole
- Where
- 48 sites in United States
- Volunteers
- 323 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
This study is aimed to evaluate the bipolar disorder symptoms in patients presented with schizophrenia, schizoaffective disorder or recurrent depression.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Recurrent Depression
- Trial name
- NCT01028196
- Where
- 3 sites in Russia
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00303602
- Testing
- Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Open-label Study of Curcumin C-3 Complex in Schizophrenia
Current evidence suggests that schizophrenia as a serious and complex psychiatric disorder, continues to challenge mental health professionals in their search for better treatment options in the community.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Depression
- Trial name
- NCT01875822
- Testing
- Super-Curcumin
- Where
- Puerto Rico
- Volunteers
- 17 people
- Sponsor
- Woodbury, Michel, M.D.
Schizophrenia, Schizoaffective Disorder
eMove - Dance/Movement Therapy Study
Schizophrenia is a chronic and severe mental disorder affecting 20 million people throughout the world and is the fourth leading cause of disability in the developed world.
- Trial name
- NCT05712928
- Testing
- Dance/movement therapy (eMove)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Drexel University
Psychotic Disorders, Schizophrenia
A Comparative Study of New Medications for Psychosis in Adolescents
The overall goal of this study is to determine the efficacy and tolerability of three atypical antipsychotic medications (risperidone, olanzapine, and quetiapine) in the treatment of adolescents with psychosis.
- Conditions
- Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
- Trial name
- NCT00222495
- Testing
- quetiapine, olanzapine, risperidone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Schizophrenia, Schizoaffective Disorder
Cerebellar Modulation of Cognition in Psychosis
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder I, Psychosis
- Trial name
- NCT06107764
- Testing
- intermittant theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS)
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Mclean Hospital
Schizophrenia, Schizoaffective Disorder
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
The purpose of this study is to investigate a safe treatment interruption interval(s) for re-initiation of bifeprunox at a therapeutic dose. The study duration is approximately 7 to 10 weeks.
- Trial name
- NCT00141479
- Testing
- Bifeprunox
- Where
- United States
- Sponsor
- Solvay Pharmaceuticals
Schizophrenia, Schizophrenia Schizoaffective
Focused Ultrasound Modulation of the Globus Pallidus Interna in Schizophrenia
This is a single-site, phase 2, sham-controlled random-order cross-over pilot trial of PLIFUS targeting the right GPi in individuals with schizophrenia.
- Trial name
- NCT05643196
- Testing
- PLIFUS, MRI
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Schizophrenia, Schizo Affective Disorder
Feasibility and Acceptability of Mobile Mental Health App for SZ and SZA
A new mental health application will be developed for persons with schizophrenia and schizoaffective disorder. The aim is to look at whether it is feasible to use a mobile health application for improving medication adherence in…
- Trial name
- NCT06474325
- Testing
- Intervention via mobile application
- Where
- India
- Volunteers
- 44 people
- Sponsor
- University of Pittsburgh
Schizophrenia
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.
- Trial name
- NCT00690274
- Testing
- BF2.649
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia Schizoaffective
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or…
- Trial name
- NCT04567524
- Testing
- LYN-005
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Lyndra Inc.
Schizophrenia
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
This is a single-center, randomized, single-blind, placebo-controlled, ascending single oral dose study designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of SEP-363856 and its metabolite SEP-363854…
- Trial name
- NCT01940159
- Testing
- SEP-363856
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
This study was conducted to examine the efficacy and tolerability of ziprasidone intramuscular (IM), and to assess the effect of switching from IM to oral ziprasidone for the treatment of acute exacerbation of schizophrenia and…
- Trial name
- NCT00650429
- Testing
- Ziprasidone
- Where
- 4 sites in Mexico
- Volunteers
- 28 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia
Treatment of schizophrenia currently includes antipsychotic medications and cognitive therapies which improve some symptoms, but do not sufficiently restore cognitive functioning or reduce psychosocial disability.
- Trial name
- NCT04857983
- Testing
- Memantine
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Effectiveness of Ziprasidone for Patients With Schizophrenia
This study is designed with the aim to evaluate the clinical effect of the overlapped switching to ziprasidone as well as the efficacy and safe metabolic profile of ziprasidone.
- Trial name
- NCT01198353
- Testing
- Ziprasidone
- Where
- 6 sites in South Korea
- Volunteers
- 67 people
- Sponsor
- Soonchunhyang University Hospital
Schizophrenia, Schizoaffective Disorder
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
A ten week, blinded trial of vitamin D vs. placebo in 80 patients with schizophrenia or schizoaffective disorder who have low blood levels of vitamin D and elevated blood levels of the amino acid proline.
- Trial name
- NCT02197286
- Testing
- Cholecalciferol
- Where
- United States
- Sponsor
- NYU Langone Health
Schizophrenia, Schizoaffective Disorder
Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine
Weight gain is a serious, common side effect of many antipsychotic medications. On average, the highest amounts of weight gain are found to occur in people taking clozaril and olanzapine, but with significant weight gain occuring…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Mood Disorders
- Trial name
- NCT00312598
- Testing
- Aripiprazole
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness
Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- Wellness (NCT00661869)
- Testing
- Wellness Program
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Manhattan Psychiatric Center
Schizophrenia, Schizo Affective Disorder
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
This 16 week clinical trial investigates a precision-medicine approach to schizophrenia by targeting a biologically distinct subgroup,-approximately one-third of patients-characterized by the presence of anti-gliadin antibodies…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Healthy
- Trial name
- NCT07615075
- Testing
- IL-23
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore